Do Options Traders Know Something About IMAX Stock We Don't?
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for IMAX shares, but what is the fundamental picture for the company? Currently, IMAX is a Zacks Rank #4 (Sell) in the Film and Television Production and Distribution industry that ranks in the Bottom 31% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while three analysts have revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from 30 cents per share to 28 cents in that period.
Given the way analysts feel about IMAX right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Looking to Trade Options?
Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.
Click to see the trades now >>
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
IMAX Corporation (IMAX): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
20 minutes ago
- CBC
How should Canada respond to U.S. tariff increase?
As U.S. President Donald Trump bumps up import tariffs on non-CUSMA-compliant Canadian goods to 35 per cent, the Power & Politics panel of party insiders discusses how Canada should respond and whether there should be an expiration date on negotiations.
Globe and Mail
21 minutes ago
- Globe and Mail
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the 'Company') (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Aug. 1, 2025, the Compensation Committee of the Company's Board of Directors (the 'Compensation Committee') granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 39,000 shares of common stock to 5 new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $10.59 per share, the Company's closing sales price on Aug. 1, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company's 2024 Inducement Plan and the terms and conditions of an applicable stock option agreement covering the grant. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. For more information, visit
Globe and Mail
21 minutes ago
- Globe and Mail
Baytex Energy Reports Strong Q2 2025 Results and Announces October Dividend
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Baytex Energy ( (TSE:BTE)) has provided an announcement. Baytex Energy Corp. reported solid second-quarter results for 2025, highlighted by record well performance in the Pembina Duvernay region and continued debt reduction. The company also announced a quarterly dividend for October 2025, reflecting its strong financial position and commitment to returning value to shareholders. The most recent analyst rating on (TSE:BTE) stock is a Buy with a C$5.50 price target. To see the full list of analyst forecasts on Baytex Energy stock, see the TSE:BTE Stock Forecast page. Spark's Take on TSE:BTE Stock According to Spark, TipRanks' AI Analyst, TSE:BTE is a Outperform. Baytex Energy's strong financial performance and positive technical indicators are the primary drivers of its solid stock score. Despite challenges from commodity prices, the company's strategic debt reduction and cash flow focus provide stability. To see Spark's full report on TSE:BTE stock, click here. More about Baytex Energy Baytex Energy Corp. is a Canadian energy company primarily involved in the exploration, development, and production of oil and natural gas. The company focuses on operations in key resource plays in North America, including the Pembina Duvernay region. Average Trading Volume: 6,145,983 Technical Sentiment Signal: Sell Current Market Cap: C$2.32B See more insights into BTE stock on TipRanks' Stock Analysis page.
